JP2023542137A - 白斑の局所処置 - Google Patents

白斑の局所処置 Download PDF

Info

Publication number
JP2023542137A
JP2023542137A JP2023517314A JP2023517314A JP2023542137A JP 2023542137 A JP2023542137 A JP 2023542137A JP 2023517314 A JP2023517314 A JP 2023517314A JP 2023517314 A JP2023517314 A JP 2023517314A JP 2023542137 A JP2023542137 A JP 2023542137A
Authority
JP
Japan
Prior art keywords
week
patient
vitiligo
ruxolitinib
cream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542137A5 (cg-RX-API-DMAC10.html
Inventor
バトラー，キャスリーン
リー，ジム
スン，カン
クオ，フィオナ
ハウエル，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/023,269 external-priority patent/US20210030672A1/en
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2023542137A publication Critical patent/JP2023542137A/ja
Publication of JP2023542137A5 publication Critical patent/JP2023542137A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2023517314A 2020-09-16 2021-09-16 白斑の局所処置 Pending JP2023542137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/023,269 US20210030672A1 (en) 2019-06-10 2020-09-16 Topical treatment of vitiligo by a jak inhibitor
US17/023,269 2020-09-16
PCT/US2021/071479 WO2022061351A1 (en) 2020-09-16 2021-09-16 Topical treatment of vitiligo

Publications (2)

Publication Number Publication Date
JP2023542137A true JP2023542137A (ja) 2023-10-05
JP2023542137A5 JP2023542137A5 (cg-RX-API-DMAC10.html) 2024-08-30

Family

ID=78135236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517314A Pending JP2023542137A (ja) 2020-09-16 2021-09-16 白斑の局所処置

Country Status (6)

Country Link
US (2) US20230364095A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213800A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023542137A (cg-RX-API-DMAC10.html)
CN (1) CN116261447A (cg-RX-API-DMAC10.html)
CA (1) CA3195357A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022061351A1 (cg-RX-API-DMAC10.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529214A (ja) * 2010-05-21 2013-07-18 インサイト・コーポレイション Ｊａｋ阻害剤の局所製剤
JP2018526362A (ja) * 2015-08-14 2018-09-13 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 円形脱毛症の処置のためのバイオマーカー
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
JP2020504719A (ja) * 2016-12-16 2020-02-13 ユニヴェルシテ・ドゥ・ボルドー Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
KR20160042064A (ko) * 2013-08-09 2016-04-18 군제 가부시키가이샤 골 재생 재료 키트, 페이스트상 골 재생 재료, 골 재생 재료 및 골 접합재
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
US20170266289A1 (en) * 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
US11957931B2 (en) * 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
BR112020013976A2 (pt) * 2018-01-09 2020-12-08 Dermavant Sciences GmbH Composições farmacêuticas para pele tópicas que contêm cerdulatinibe e usos das mesmas
US20210030672A1 (en) * 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529214A (ja) * 2010-05-21 2013-07-18 インサイト・コーポレイション Ｊａｋ阻害剤の局所製剤
JP2018526362A (ja) * 2015-08-14 2018-09-13 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 円形脱毛症の処置のためのバイオマーカー
JP2020504719A (ja) * 2016-12-16 2020-02-13 ユニヴェルシテ・ドゥ・ボルドー Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE LANCET, vol. 396(10244):110-120, JPN6025029943, 2020, ISSN: 0005787571 *

Also Published As

Publication number Publication date
CA3195357A1 (en) 2022-03-24
WO2022061351A1 (en) 2022-03-24
US20230293431A1 (en) 2023-09-21
EP4213800A1 (en) 2023-07-26
US20230364095A1 (en) 2023-11-16
CN116261447A (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
US12233067B2 (en) Topical treatment of vitiligo by a JAK inhibitor
KR20140004186A (ko) 표면활성제 조성물
CN106922128B (zh) 睾酮制剂及其治疗方法
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US12589096B2 (en) Ruxolitinib formulation for reduction of itch in atopic dermatitis
US11878008B2 (en) Composition for preventing or treating atopic dermatitis
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
KR20180094915A (ko) 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물
WO2019113475A1 (en) Topical ointment formulations and their use in treating skin conditions
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak
US20210052538A1 (en) Tinted cold sore formulation
US20260102359A1 (en) Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation
WO2025096373A1 (en) Ruxolitinib for use in the treatment of prurigo nodularis
GB2616294A (en) Composition for use
JP2024509383A (ja) アトピー性皮膚炎及びその他の皮膚状態の治療のためのｊａｋ１／３阻害剤の局所製剤及びその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260203